13 Result(s)

Article

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Jason Aldred, Eric Freire-Alvarez, Alexander V. Amelin… in Neurology and Therapy (2023)

Article

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Foslevodopa/foscarbidopa, a soluble formulation of levodopa/carbidopa (LD/CD) prodrugs for the treatment of Parkinson’s disease (PD), is administered as a 24-hour/day continuous subcutaneous infusion (CSCI) wi...

Jason Aldred, Eric Freire-Alvarez, Alexander V. Amelin… in Neurology and Therapy (2023)

Article

Blood biomarker-based classification study for neurodegenerative diseases

As the population ages, neurodegenerative diseases are becoming more prevalent, making it crucial to comprehend the underlying disease mechanisms and identify biomarkers to allow for early diagnosis and effect...

Jack Kelly, Rana Moyeed, Camille Carroll, Shouqing Luo, **nzhong Li in Scientific Reports (2023)

Article

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease

The genetic basis of levodopa-induced-dyskinesia (LiD) is poorly understood, and there have been few well-powered genome-wide studies. We performed a genome-wide survival meta-analyses to study the effect of g...

Alejandro Martinez-Carrasco, Raquel Real, Michael Lawton… in npj Parkinson's Disease (2023)

Article

Implications of research that excludes under-served populations

Effective translation of evidence from clinical trials into clinical practice requires the enrolment of diverse, representative trial populations. However, this diversity is still often lacking, with negative ...

Lynn Rochester, Camille Carroll in Nature Reviews Neurology (2022)

Article

A report from the NIHR UK working group on remote trial delivery for the COVID-19 pandemic and beyond

Prior to the COVID-19 pandemic, the majority of clinical trial activity took place face to face within clinical or research units. The COVID-19 pandemic resulted in a significant shift towards trial delivery w...

Jane A. H. Masoli, Kim Down, Gary Nestor, Sharon Hudson, John T. O’Brien… in Trials (2021)

Article

Develo** a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process

Participants in clinical research studies often do not reflect the populations for which healthcare interventions are needed or will be used. Enhancing representation of under-served groups in clinical researc...

Miles D. Witham, Eleanor Anderson, Camille Carroll, Paul M. Dark, Kim Down… in Trials (2020)

Article

Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease

Parkinson’s disease (PD) and Alzheimer’s disease (AD) are the most common neurodegenerative diseases and have been suggested to share common pathological and physiological links. Understanding the cross-talk b...

Jack Kelly, Rana Moyeed, Camille Carroll, Diego Albani, **nzhong Li in Molecular Brain (2019)

Article

Two-arm randomised futility trials: PD-stat - a futility trial of a potential neuroprotective treatment in people with Parkinson's disease

Siobhan Creanor, Jane Vickery, Vicky Eyre, John Zajicek, Sue Ball, Jordan Elm… in Trials (2015)

Article

People with Parkinson's design clinical trials charter to improve communication about, recruitment to and retention in Parkinson's clinical trials

Jon Stamford, Tom Isaacs, Camille Carroll in Trials (2015)